

STUDY OF THE REACTIVITY OF 5-ALKYNYL-4-CHLORO- AND 4-ALKYNYL-5-CHLOROPYRIDAZIN-3(2H)-ONES TOWARDS OXYGEN AND SULFUR NUCLEOPHILES

Omar R'kyek, Bert U.W. Maes, Guy L.F. Lemièr^{*}, and Roger A. Dommisse

Department of Chemistry, University of Antwerp (RUCA),

Groenenborgerlaan 171, B-2020 Antwerp, Belgium

Abstract- A study of the reactivity of 5-alkynyl-4-chloro- (**1a,b**) and 4-alkynyl-5-chloropyridazin-3(2H)-ones (**4a,b**) towards oxygen and sulfur nucleophiles (NaOCH₃, NaSCH₃, KOH and Na₂S) is reported. The synthesis of 5-alkynyl-2-methyl-4-methoxy- (**2a,b**) and 5-alkynyl-2-methyl-4-methylthiopyridazin-3(2H)-ones (**3a,b**) and their regioisomers 4-alkynyl-2-methyl-5-methoxy- (**5a,b**) and 4-alkynyl-2-methyl-5-methylthiopyridazin-3(2H)-ones (**6a,b**) is described, as well as the synthesis of 2-substituted 6-methylfuro[2,3-*d*]- (**7a,b,c**) and 2-substituted 6-methylthieno[2,3-*d*]pyridazin-7(6H)-ones (**8a,b**) and their regioisomers 2-substituted 5-methylfuro[2,3-*d*]- (**9a,b,c**) and 2-substituted 5-methylthieno[2,3-*d*]pyridazin-4(5H)-ones (**10a,b**).


Recently, we described an efficient approach towards unsymmetrically disubstituted dialkynylpyridazin-3(2H)-ones.¹ The key step in their synthesis is the performance of a selective Sonogashira cross-coupling reaction on 4-chloro-2-methyl-5-trifluoromethanesulfonyloxy pyridazin-3(2H)-one or its regioisomer, which allows the preparation of 5-alkynyl-4-chloro-2-methyl- and 4-alkynyl-5-chloro-2-methylpyridazin-3(2H)-ones respectively.¹ These monoalkynylated pyridazinones are useful intermediates for the synthesis of new pyridazinone based compounds.² They allow the performance of a second palladium-catalysed cross-coupling reaction (Sonogashira or Suzuki reaction) as described earlier,¹ but should also permit a wide variety of other reactions on the chlorinated carbon atom as well as on the triple bond. In this paper, we present the reactivity of 5-alkynyl-4-chloro-2-methyl- and 4-alkynyl-5-chloro-2-methylpyridazin-

3(2*H*)-ones towards oxygen and sulfur nucleophiles, resulting in the formation of alkoxy- and alkylthioalkynylpyridazinones (**2**, **3**, **5** and **6**) as well as bicyclic furo- and thienopyridazinones (**7-10**).

In a previous paper, we described Suzuki arylations on 4-chloro-5-methoxy-2-methylpyridazin-3(2*H*)-one and its regioisomer 5-chloro-4-methoxy-2-methylpyridazin-3(2*H*)-one using Pd(PPh₃)₄ as the catalyst.^{3,4} Similarly, a direct Sonogashira alkylation of these chloromethoxypyridazinones would be the shortest way to synthesize compounds of type **2** and **5**. However, attempts to perform a Sonogashira cross-coupling reaction with phenylacetylene using Pd(PPh₃)₂Cl₂ as precatalyst were unsuccessful, and gave only traces of the desired compounds. Trials to use Et₃N both as base and as the solvent, or to change the solvent from THF to DMF, for the alkylation of 4-chloro-5-methoxy-2-methylpyridazin-3(2*H*)-one were all in vain. Also, other palladium catalysts (Pd(PPh₃)₄ and Pd(dppf)Cl₂) were used in hope to obtain 5-methoxy-2-methyl-4-phenylethynylpyridazin-3(2*H*)-one (**5a**), however, no satisfactory results were achieved.

These negative results prompted us to examine nucleophilic substitution reactions on the chlorinated carbon atom in C-4 or C-5 position of the 5-alkynyl-4-chloro-2-methyl- (**1a,b**) and 4-alkynyl-5-chloro-2-methylpyridazin-3(2*H*)-ones (**4a,b**) respectively using CH₃O⁻ and CH₃S⁻ as the nucleophiles. When reacting **1a,b** with NaOCH₃ and NaSCH₃ in dioxane at room temperature, 5-alkynyl-2-methyl-4-methoxy- (**2a,b**) and 5-alkynyl-4-methylthio-2-methylpyridazin-3(2*H*)-ones (**3a,b**) respectively were successfully obtained in moderate to good yields (Table 1).

Table 1: Nucleophilic substitution reactions of compounds (**1a,b**).




Product	R	X	Reaction time (h)	Yield (%)
2a	C ₆ H ₅	O	2	55 ^a
2b	C ₃ H ₇	O	2	57 ^a
3a	C ₆ H ₅	S	2	70 ^b
3b	C ₃ H ₇	S	19	90 ^b

^aReaction conditions: **1a** or **1b** (1 mmol); 4.86 M NaOCH₃ (1.07 mmol); dioxane (4.3 mL) at room temperature.

^bReaction conditions: **1a** or **1b** (1 mmol); NaSCH₃ (1.6 mmol); dioxane (5.5 mL) at room temperature.

When the 4-alkynyl-5-chloro-2-methylpyridazin-3(2*H*)-ones (**4a,b**) were subjected to identical nucleophilic substitution conditions (NaOCH₃ or NaSCH₃ in dioxane), only 5-methoxy-2-methyl-4-phenylethynylpyridazin-3(2*H*)-one (**5a**) was obtained in good yield (Table 2). The reaction of **4a** with NaSCH₃ and **4b** with NaOCH₃ or NaSCH₃ in dioxane gave a mixture of products due to nucleophilic addition on the triple bond (as shown by MS, ¹H-NMR and ¹³C-NMR spectra).⁵ To overcome this problem, dioxane was replaced by methanol, which is known to favor nucleophilic attack in C-5 over C-4 position in the case of 2-substituted 4,5-dichloropyridazin-3(2*H*)-ones.⁶ In this way, compounds (**5b**) and (**6a,b**) were obtained (Table 2).

Table 2: Nucleophilic substitution reactions of compounds (**4a,b**).



Product	R	X	Solvent	Reaction time (h)	Yield (%)
5a	C ₆ H ₅	O	dioxane	2	90 ^a
5b	C ₃ H ₇	O	methanol	10	36 ^{a,b}
6a	C ₆ H ₅	S	methanol	3	90 ^c
6b	C ₃ H ₇	S	methanol	1.5	38 ^{b,c}

^aReaction conditions: **4a** or **4b** (1 mmol); 4.86 M NaOCH₃ (1.07 mmol); solvent (4.3 mL) at room temperature.


^bNo starting material was recovered.

^cReaction conditions: **4a** or **4b** (1 mmol); NaSCH₃ (1.6 mmol); methanol (5.5 mL) at room temperature.

Furthermore, encouraged by the reported biological activities of the furo- and thienopyridazine and pyridazinone derivatives,⁷ we examined the preparation of 2-substituted 6-methylfuro[2,3-*d*]- (**7a,b,c**) and 2-substituted 6-methylthieno[2,3-*d*]pyridazin-7(6*H*)-ones (**8a,b**) and their regioisomers 2-substituted 5-methylfuro[2,3-*d*]- (**9a,b,c**) and 2-substituted 5-methylthieno[2,3-*d*]pyridazin-4(5*H*)-ones (**10a,b**). In the earliest reports, the preparation of these fused compounds was based on the reaction of a hydrazine with a 2,3-dicarbonylated furan or thiophene to form the pyridazine moiety (Figure 1, way a).⁸ We now report a different and smooth method, based on the reaction of an *ortho*-alkynyl-chloropyridazin-3(2*H*)-one with KOH or Na₂S (Figure 1, way b). The mechanism of these ring closure reactions, can be

considered as a nucleophilic addition reaction on the triple bond of the alkynyl-chloropyridazin-3(2*H*)-ones with a hydroxide or sulfide anion, followed by an intramolecular nucleophilic substitution,⁹ or the opposite,¹⁰ or the two mechanisms may occur simultaneously. The choice of different alkynyl groups in the selective Sonogashira cross-coupling reaction permits the introduction of the desired substituent at the C-2 position of the furo[2,3-*d*]- and thieno[2,3-*d*]pyridazinones. The retrosynthetic analysis of our new (way b) and the literature pathways (way a), shows the difference between the two methodologies (Figure 1).


Figure 1: Retrosynthetic analysis of the literature and the new pathway of ring closure reactions.



Treatment of 5-alkynyl-4-chloro-2-methyl- (**1a,b**) and 4-alkynyl-5-chloro-2-methylpyridazin-3(2*H*)-ones (**4a,b**) with an aqueous solution of KOH in dioxane^{9b} yielded 2-substituted 6-methylfuro[2,3-*d*]pyridazin-

7(6*H*)-ones (**7a,b**) and 2-substituted 5-methylfuro[2,3-*d*]pyridazin-4(5*H*)-ones (**9a,b**) respectively (Tables 3 and 4). The very low yield of the compounds (**7b**) and (**9b**) (Tables 3 and 4) was assumed to be due to the acidity of the protons in the C-3' position of the pentynyl group of **1b** and **4b**. To examine this assumption, we prepared 4-chloro-2-methyl-5-*tert*-butylethynyl- (**1c**) and 5-chloro-2-methyl-4-*tert*-butylethynylpyridazin-3(2*H*)-one (**4c**).¹ Subsequent treatment of **1c** and **4c** with an aqueous solution of KOH in dioxane led to the formation of 6-methyl-2-*tert*-butylfuro[2,3-*d*]pyridazin-7(6*H*)-one (**7c**) and 5-methyl-2-*tert*-butylfuro[2,3-*d*]pyridazin-4(5*H*)-one (**9c**) in 65 % and 52 % yields respectively (Tables 3 and 4). These observations support the idea that the acidity of the propargylic protons indeed is responsible for the failure to cyclise **1b** and **4b**.

Table 3: Ring closure reactions of compounds (**1a,b,c**).




Product	R	X (MX)	Solvent	Temperature	Reaction time (h)	Yield (%)
7a	C ₆ H ₅	O (KOH)	dioxane	100°C	4	80 ^a
7b	C ₃ H ₇	O (KOH)	dioxane	100°C	2	4 ^{a,b}
7c	C(CH ₃) ₃	O (KOH)	dioxane	100°C	20	65 ^a
8a	C ₆ H ₅	S (Na ₂ S)	DMF	60°C	0.75	72 ^c
8b	C ₃ H ₇	S (Na ₂ S)	DMF	60°C	0.75	60 ^c

^aReaction conditions: **1a** or **1b** or **1c** (1 mmol); KOH (13 mmol); H₂O (4.6 mL); dioxane (9 mL) at 100°C.

^bNo starting material was recovered.

^cReaction conditions: **1a** or **1b** (1 mmol); (Na₂S.9H₂O) (2.2 mmol); DMF (4.6 mL) at 60°C.

Similarly, by reacting 5-alkynyl-4-chloro-2-methyl- (**1a,b**) and 4-alkynyl-5-chloro-2-methylpyridazin-3(2*H*)-ones (**4a,b**) with sodium sulfide (Na₂S.9H₂O) in DMF, the expected ring closure reactions occurred providing 2-substituted 6-methylthieno[2,3-*d*]pyridazin-7(6*H*)-ones (**8a,b**) and 2-substituted 5-methylthieno[2,3-*d*]pyridazin-4(5*H*)-ones (**10a,b**) (Tables 3 and 4).^{9b}

Table 4: Ring closure reactions of compounds (**4a,b,c**).

Product	R	X (MX)	Solvent	Temperature	Reaction time (h)	Yield (%)
9a	C ₆ H ₅	O (KOH)	dioxane	100°C	10	50 ^a
9b	C ₃ H ₇	O (KOH)	dioxane	100°C	20	3 ^{a,b}
9c	C(CH ₃) ₃	O (KOH)	dioxane	100°C	13	52 ^a
10a	C ₆ H ₅	S (Na ₂ S)	DMF	60°C	0.75	79 ^c
10b	C ₃ H ₇	S (Na ₂ S)	DMF	60°C	0.50	19 ^{b,c}

^aReaction conditions: **4a** or **4b** or **4c** (1 mmol); KOH (13 mmol); H₂O (4.6 mL); dioxane (9 mL) at 100°C.

^bNo starting material was recovered.

^cReaction conditions: **4a** or **4b** (1 mmol); (Na₂S·9H₂O) (2.2 mmol); DMF (4.6 mL) at 60°C.

In conclusion, by performing nucleophilic substitution reactions on alkynyl-chloropyridazinones with alkoxides and alkylthiolates, alkoxy-alkynyl- and alkylthio-alkynylpyridazinones were easily prepared. Moreover, starting from the same starting materials, reactions with hydroxide and sulfide anions yielded bicyclic furo[2,3-*d*]- and thieno[2,3-*d*]pyridazinones respectively.

EXPERIMENTAL

¹H-NMR and ¹³C-NMR spectra were recorded on a Varian Unity 400 spectrometer in CDCl₃ with TMS as the internal standard. Chemical shifts are given in ppm and *J* values in Hz. The multiplicity of the signals is indicated by the following abbreviations: s singlet, d doublet, t triplet, q quadruplet, h hexaplet and m multiplet. HRMS and product ion spectra were recorded on a quadrupole-time of flight mass spectrometer (QToF 2, Micromass, Manchester, UK) equipped with a standard electrospray ionisation (ESI) interface. Samples were dissolved in CH₃OH containing 0.1 % formic acid and diluted to a concentration of approximately 10⁻⁵ mol/L. 1μL injections were directed to the mass spectrometer at a flow rate of 5μL/min CH₃OH (0.1% formic acid), using the CapLC HPLC system (Waters, Millford).

Product ion spectra were recorded selecting the protonated molecule $[M+H]^+$ in the quadrupole. This precursor ion is fragmented in the collision cell using Ar as collision gas and a collision energy of 20, 25 and 30 eV. IR spectra were obtained as potassium bromide pellets with a Bruker Vector 22 spectrometer. Melting points were recorded using a Büchi B-545 apparatus and are uncorrected. All reagents were purchased from commercial sources (Acros, Aldrich) and were used as such. Dioxane 99+ % (Acros) was dried over sodium/benzophenone and freshly distilled before use. DMF 99.9 % (Acros) was used as such. Flash column chromatography was performed on Kiesel gel 60 (Merck), 0.040-0.063 mm.

General procedure for the preparation of the 5-alkynyl-2-methyl-4-methoxy- (2a,b) and the 4-alkynyl-2-methyl-5-methoxypyridazin-3(2H)-ones (5a,b):

To a solution of 5-alkynyl-4-chloro- (**1a,b**) or 4-alkynyl-5-chloro-2-methylpyridazin-3(2H)-ones (**4a,b**) (1 mmol) in dioxane (4.3 mL) a 4.86 M NaOCH₃ solution (0.22 mL, 1.07 mmol) was added. The reaction mixture was stirred at rt (the flask was equipped with a drying tube) until total consumption of the starting material (TLC analysis and/or DCI-MS). The mixture was then poured into water (60 mL) and extracted with EtOAc (3x75 mL). After drying over MgSO₄, the solvent was removed under reduced pressure. The residue was purified by column chromatography when indicated.

4-Methoxy-2-methyl-5-phenylethynylpyridazin-3(2H)-one (2a). No column chromatography was performed. Yield 55%; pale brown solid; mp 65.3°C (Hexane/Petroleum ether); δ_H (CDCl₃): 7.67 (s, 1H, H-6), 7.55-7.50 (m, 2H, H_{Ph}-2,6), 7.42-7.35 (m, 3H, H_{Ph}-3,4,5), 4.41 (s, 3H, OCH₃), 3.76 (s, 3H, NCH₃); δ_C (CDCl₃): 157.26 (C-3), 155.15 (C-4), 138.64 (C-6), 131.69 (C_{Ph}-2,6), 129.45 (C_{Ph}-4), 128.57 (C_{Ph}-3,5), 122.04 (C_{Ph}-1), 109.59 (C-5), 99.19 (C-2"), 81.11 (C-1"), 60.49 (OCH₃), 40.03 (NCH₃); ν_{max} (KBr): 2925, 2854, 2214, 1654, 1606, 1525, 1334, 1007, 759, 691, 528 cm⁻¹; MS (ESI) m/z: 241 (100%), 197, 142, 115, 91; HRMS (ESI) for C₁₄H₁₃N₂O₂ $[M+H]^+$: calcd 241.0977, found 241.0975; Anal. Calcd for C₁₄H₁₂N₂O₂: C, 69.99; H, 5.03; N, 11.66. Found: C, 70.06; H, 4.99; N, 11.76.

4-Methoxy-2-methyl-5-(pent-1-ynyl)pyridazin-3(2H)-one (2b). No column chromatography was performed. Yield 57%; brownish oil; δ_H (CDCl₃): 7.55 (s, 1H, H-6), 4.31 (s, 3H, OCH₃), 3.73 (s, 3H, NCH₃), 2.43 (t, $J = 7.0$ Hz, 2H, H-3"), 1.64 (h, $J = 7.3$ Hz, 2H, H-4"), 1.04 (t, $J = 7.3$ Hz, 3H, H-5"); δ_C (CDCl₃): 157.48 (C-3), 155.13 (C-4), 139.26 (C-6), 110.73 (C-5), 101.50 (C-2"), 72.81 (C-1"), 60.27 (OCH₃), 39.94 (NCH₃), 21.80, 21.79 (C-3" or C-4"), 13.50 (C-5"); ν_{max} (liquid film): 2964, 2936, 2873, 2229, 1651, 1597, 1457, 1311, 1051, 1004, 923, 783, 647 cm⁻¹; MS (ESI) m/z: 207, 177, 164, 151 (100%); HRMS (ESI) for C₁₁H₁₅N₂O₂ $[M+H]^+$: calcd 207.1134, found 207.1137; Anal. Calcd for C₁₁H₁₄N₂O₂: C, 64.06; H, 6.84; N, 13.58. Found: C, 64.13; H, 6.81; N, 13.47.

5-Methoxy-2-methyl-4-phenylethynylpyridazin-3(2H)-one (5a). No column chromatography was performed. Yield 90%; pale brown solid; mp 116.2°C (Ethanol); δ_{H} (CDCl₃): 7.74 (s, 1H, H-6), 7.61-7.55 (m, 2H, H_{Ph}-2,6), 7.36-7.32 (m, 3H, H_{Ph}-3,4,5), 4.12 (s, 3H, OCH₃), 3.79 (s, 3H, NCH₃); δ_{C} (CDCl₃): 160.97, 159.63 (C-5 or C-3), 131.93 (C_{Ph}-2,6), 128.95 (C_{Ph}-4), 128.31 (C_{Ph}-3,5), 127.34 (C-6), 122.87 (C_{Ph}-1), 106.01 (C-2'), 102.84 (C-4), 79.99 (C-1'), 57.77 (OCH₃), 40.35 (NCH₃); ν_{max} (KBr): 2957, 2925, 2854, 2204, 1635, 1345, 1284, 1177, 1124, 968, 760, 694, 529, 481 cm⁻¹; MS (ESI) m/z: 241, 226, 199, 143, 102 (100%); HRMS (ESI) for C₁₄H₁₃N₂O₂ [M+H]⁺: calcd 241.0977, found 241.0975; Anal. Calcd for C₁₄H₁₂N₂O₂: C, 69.99; H, 5.03; N, 11.66. Found: C, 69.90; H, 5.13; N, 11.70.

5-Methoxy-2-methyl-4-(pent-1-ynyl)pyridazin-3(2H)-one (5b). This compound was prepared using the general procedure, but instead of dioxane MeOH has been used as the solvent. Chromatography eluent: Hexane/EtOAc 4:6; Yield 36%; pale yellow solid; mp 107.6°C (Hexane/Petroleum ether); δ_{H} (CDCl₃): 7.69 (s, 1H, H-6), 4.06 (s, 3H, OCH₃), 3.76 (s, 3H, NCH₃), 2.51 (t, $J = 7.2$ Hz, 2H, H-3'), 1.66 (h, $J = 7.3$ Hz, 2H, H-4'), 1.06 (t, $J = 7.3$ Hz, 3H, H-5'); δ_{C} (CDCl₃): 167.08, 159.62 (C-5 or C-3), 127.35 (C-6), 106.68, 105.23 (C-2' or C-4), 71.28 (C-1'), 57.63 (OCH₃), 40.29 (NCH₃), 22.25, 21.96 (C-3' or C-4'), 13.52 (C-5'); ν_{max} (KBr): 2964, 2932, 2226, 1629, 1586, 1336, 1283, 1249, 1158, 1005, 958, 890, 755, 493; MS (ESI) m/z: 207, 163, 153, 123 (100%); HRMS (ESI) for C₁₁H₁₅N₂O₂ [M+H]⁺: calcd 207.1134, found 207.1133; Anal. Calcd for C₁₁H₁₄N₂O₂: C, 64.06; H, 6.84; N, 13.58. Found: C, 63.97; H, 6.92; N, 13.50.

General procedure for the preparation of the 5-alkynyl-2-methyl-4-methylthio- (3a,b) and the 4-alkynyl-2-methyl-5-methylthiopyridazin-3(2H)-ones (6a,b):

To a solution of 5-alkynyl-4-chloro- (**1a,b**) or 4-alkynyl-5-chloro-2-methylpyridazin-3(2H)-ones (**4a,b**) (1 mmol) in dioxane (5.5 mL) NaSCH₃ (0.11 g, 1.6 mmol) was added. The reaction mixture was stirred at rt (the flask was equipped with a drying tube) until total consumption of the starting material (TLC analysis and/or DCI-MS). The reaction mixture was then poured into water (70 mL) and extracted with EtOAc (3x85 mL). After drying over MgSO₄, the solvent was removed under reduced pressure. The residue was purified by column chromatography when indicated.

4-Methylthio-2-methyl-5-phenylethynylpyridazin-3(2H)-one (3a). Chromatography eluent: Heptane/Ether 1:1; Yield 70%; yellowish solid; mp 95.2°C (Ethanol); δ_{H} (CDCl₃): 7.64 (s, 1H, H-6), 7.58-7.53 (m, 2H, H_{Ph}-2,6), 7.44-7.36 (m, 3H, H_{Ph}-3,4,5), 3.76 (s, 3H, NCH₃), 2.85 (s, 3H, SCH₃); δ_{C} (CDCl₃): 158.65 (C-3), 142.63 (C-4), 137.22 (C-6), 131.77 (C_{Ph}-2,6), 129.75 (C_{Ph}-4), 128.63 (C_{Ph}-3,5), 123.12 (C-5),

121.78 (C_{Ph}-1), 102.45 (C-2"), 83.29 (C-1"), 40.36 (NCH₃), 16.33 (SCH₃); ν_{\max} (KBr): 2927, 2203, 1626, 1492, 1371, 1249, 1047, 860, 758, 692, 535 cm⁻¹; MS (ESI) m/z: 257, 214, 200 (100%), 167, 129; HRMS (ESI) for C₁₄H₁₃N₂OS [M+H]⁺: calcd 257.0749, found 257.0739; Anal. Calcd for C₁₄H₁₂N₂OS: C, 65.60; H, 4.72; N, 10.93. Found: C, 65.53; H, 4.82; N, 11.12.

4-Methylthio-2-methyl-5-(pent-1-ynyl)pyridazin-3(2H)-one (3b). No column chromatography was performed. Yield 90%; brownish oil; δ_{H} (CDCl₃): 7.52 (s, 1H, H-6), 3.73 (s, 3H, NCH₃), 2.77 (s, 3H, SCH₃), 2.48 (t, $J = 7.0$ Hz, 2H, H-3"), 1.66 (h, $J = 7.3$ Hz, 2H, H-4"), 1.06 (t, $J = 7.3$ Hz, 3H, H-5"); δ_{C} (CDCl₃): 158.86 (C-3), 141.89 (C-4), 137.69 (C-6), 124.30 (C-5), 105.28 (C-2"), 75.28 (C-1"), 40.32 (NCH₃), 21.93, 21.73 (C-3" or C-4"), 16.22 (SCH₃), 13.56 (C-5"); ν_{\max} (liquid film): 2929, 2856, 2226, 1732, 1643, 1488, 1370, 1145, 861, 778, 690 cm⁻¹; MS (ESI) m/z: 223, 193, 180, 167, 151, 137 (100%), 124; HRMS (ESI) for C₁₁H₁₅N₂OS [M+H]⁺: calcd 223.0905, found 223.0911; Anal. Calcd for C₁₁H₁₄N₂OS: C, 59.43; H, 6.35; N, 12.60. Found: C, 59.31; H, 6.25; N, 12.72.

5-Methylthio-2-methyl-4-phenylethynylpyridazin-3(2H)-one (6a). This compound was prepared using the general procedure, but instead of dioxane MeOH has been used as the solvent.

No column chromatography was performed. Yield 97%; yellowish solid; mp 131°C (Ethanol); δ_{H} (CDCl₃): 7.67 (s, 1H, H-6), 7.64-7.59 (m, 2H, H_{Ph}-2,6), 7.40-7.32 (m, 3H, H_{Ph}-3,4,5), 3.79 (s, 3H, NCH₃), 2.60 (s, 3H, SCH₃); δ_{C} (CDCl₃): 157.68 (C-3), 147.17 (C-5), 131.26 (C_{Ph}-2,6), 131.79 (C-6), 129.23 (C_{Ph}-4), 128.46 (C-4), 128.28 (C_{Ph}-3,5), 122.32 (C_{Ph}-1), 106.61 (C-2'), 82.10 (C-1'), 40.21 (NCH₃), 14.29 (SCH₃); ν_{\max} (KBr): 2924, 2854, 2204, 1641, 1541, 1438, 1229, 1037, 936, 765, 694, 528 cm⁻¹; MS (ESI) m/z: 257 (100%), 242, 214, 200, 186, 129; HRMS (ESI) for C₁₄H₁₃N₂OS [M+H]⁺: calcd 257.0749, found 257.0748; Anal. Calcd for C₁₄H₁₂N₂OS: C, 65.60; H, 4.72; N, 10.93. Found: C, 65.53; H, 4.66; N, 10.85.

5-Methylthio-2-methyl-4-(pent-1-ynyl)pyridazin-3(2H)-one (6b). This compound was prepared using the general procedure, but instead of dioxane MeOH has been used as the solvent.

No column chromatography was performed. Yield 38%; Yellowish oil; δ_{H} (CDCl₃): 7.62 (s, 1H, H-6), 3.75 (s, 3H, NCH₃), 2.55 (s, 3H, SCH₃), 2.55 (t, $J = 7.0$ Hz, 2H, H-3'), 1.67 (h, $J = 7.0$ Hz, 2H, H-4'), 1.08 (t, $J = 7.0$ Hz, 3H, H-5'); δ_{C} (CDCl₃): 158.33 (C-3), 146.63 (C-5), 131.43 (C-6), 118.71 (C-4), 109.66 (C-2'), 73.82 (C-1'), 40.30 (NCH₃), 22.35, 21.91 (C-3' or C-4'), 14.33 (SCH₃), 13.54 (C-5'); ν_{\max} (liquid film): 3436, 2962, 2218, 1633, 1546, 1289, 1199, 964 cm⁻¹; MS (ESI) m/z: 223, 179, 153, 134, 116, 98 (100%); HRMS (ESI) for C₁₁H₁₅N₂OS [M+H]⁺: calcd 223.0905, found 223.0913; Anal. Calcd for C₁₁H₁₄N₂OS: C, 59.43; H, 6.35; N, 12.60. Found: C, 59.33; H, 6.24; N, 12.66.

General procedure for the preparation of 2-substituted 6-methylfuro[2,3-*d*]pyridazin-7(6*H*)-ones (7a,b,c) and 2-substituted 5-methylfuro[2,3-*d*]pyridazin-4(5*H*)-ones (9a,b,c):

To a solution of 5-alkynyl-4-chloro- (1a,b) or 4-alkynyl-5-chloro-2-methylpyridazin-3(2*H*)-ones (4a,b) (1 mmol) in dioxane (9 mL) a KOH solution (0.75 g, 13.4 mmol in 4.6 mL of H₂O) was added. The reaction mixture was stirred at 100°C until total consumption of the starting material (TLC analysis and/or DCI-MS). The reaction mixture was then poured into water (60 mL) and extracted with EtOAc (3x70 mL). After drying over MgSO₄, the solvent was removed under reduced pressure. The residue was purified by column chromatography.

2-Phenyl-6-methylfuro[2,3-*d*]pyridazin-7(6*H*)-one (7a). Chromatography eluent: Heptane/EtOAc 6:4; Yield 80%; yellowish solid; mp 150.4°C (Ethanol); δ_{H} (CDCl₃): 8.12 (s, 1H, H-4), 7.92-7.88 (m, 2H, H_{Ph}-2,6), 7.51-7.41 (m, 3H, H_{Ph}-3,4,5), 6.91 (s, 1H, H-3), 3.92 (s, 3H, NCH₃); δ_{C} (CDCl₃): 160.20 (C-2), 153.11 (C-7), 146.60 (C-7a), 131.60 (C-4), 129.95 (C_{Ph}-4), 128.89 (C_{Ph}-3,5), 128.49, 128.42 (C_{Ph}-1 or C-3a), 125.49 (C_{Ph}-2,6), 99.54 (C-3), 39.27 (NCH₃); ν_{max} (KBr): 3127, 2924, 2854, 1674, 1541, 1484, 1291, 1012, 920, 767, 689, 652, 492 cm⁻¹; MS (ESI) m/z: 227 (100%), 140; HRMS (ESI) for C₁₃H₁₁N₂O₂ [M+H]⁺: calcd 227.0821, found 227.0813; Anal. Calcd for C₁₃H₁₀N₂O₂: C, 69.02; H, 4.46; N, 12.38. Found: C, 69.09; H, 4.51; N, 12.29.

2-Propyl-6-methylfuro[2,3-*d*]pyridazin-7(6*H*)-one (7b). Chromatography eluent: Heptane/EtOAc 6:4; Yield 4%; brownish oil; δ_{H} (CDCl₃): 8.04 (s, 1H, H-4), 6.34 (t, *J* = 0.9 Hz, 1H, H-3), 3.89 (s, 3H, NCH₃), 2.79 (td, *J* = 7.5 Hz, 0.9 Hz, 2H, H-1'), 1.79 (h, *J* = 7.5 Hz, 2H, H-2'), 1.00 (t, *J* = 7.5 Hz, 3H, H-3'); δ_{C} (CDCl₃): 164.47 (C-7), 153.32 (C-7a), 146.65, (C-2), 131.77 (C-4), 128.18 (C-3a), 101.14 (C-3), 39.33 (NCH₃), 30.30 (C-1'), 20.97 (C-2'), 13.59 (C-3'); ν_{max} (liquid film): 2960, 2926, 2854, 1681, 1555, 1462, 1288, 1261, 1028, 962, 820, 800 cm⁻¹; MS (ESI) m/z: 193, 164, 139 (100%), 111; HRMS (ESI) for C₁₀H₁₃N₂O₂ [M+H]⁺: calcd 193.0977, found 193.0975; Anal. Calcd for C₁₀H₁₂N₂O₂: C, 62.49; H, 6.29; N, 14.57. Found: C, 62.54; H, 6.20; N, 14.67.

2-*t*-Butyl-6-methylfuro[2,3-*d*]pyridazin-7(6*H*)-one (7c). Chromatography eluent: Heptane/Acetone 8:2; Yield 65%; brownish solid; mp 121.1°C (Hexane/Petroleum ether); δ_{H} (CDCl₃): 8.03 (s, 1H, H-4), 6.31 (s, 1H, H-3), 3.89 (s, 3H, NCH₃), 1.40 (s, 9H, *t*-Bu); δ_{C} (CDCl₃): 172.03 (C-2), 153.23 (C-7), 146.48 (C-7a), 131.76 (C-4), 127.92 (C-3a), 98.28 (C-3), 39.22 (NCH₃), 33.38 [C(CH₃)₃], 28.64 [C(CH₃)₃]; ν_{max} (KBr): 3123, 2971, 2871, 1670, 1549, 1304, 1040, 931, 655, 466 cm⁻¹; MS (ESI) m/z: 207 (100%), 192, 177, 139, 111; HRMS (ESI) for C₁₁H₁₅N₂O₂ [M+H]⁺: calcd 207.1134, found 207.1129; Anal. Calcd for C₁₁H₁₄N₂O₂: C, 64.06; H, 6.84; N, 13.58. Found: C, 63.92; H, 6.76; N, 13.63.

2-Phenyl-5-methylfuro[2,3-*d*]pyridazin-4(5*H*)-one (9a). Chromatography eluent: Heptane/EtOAc 6:4 ; Yield 67%; yellowish solid; mp 178°C (Ethanol); δ_{H} (CDCl₃): 8.21 (d, $J = 0.6$ Hz, 1H, H-7), 7.83-7.79 (m, 2H, H_{Ph}-2,6), 7.50-7.39 (m, 3H, H_{Ph}-3,4,5), 7.25 (d, $J = 0.6$ Hz, 1H, H-3), 3.89 (s, 3H, NCH₃); δ_{C} (CDCl₃): 158.85, 158.45 (C-2 or C-4), 152.45 (C-7a), 129.82, 125.86 (C_{Ph}-4 or C-7), 129.13 (C_{Ph}-3,5), 128.85 (C_{Ph}-1), 125.27 (C_{Ph}-2,6), 124.54 (C-3a), 101.38 (C-3), 39.68 (NCH₃); ν_{max} (KBr): 3117, 2926, 2854, 1668, 1541, 1456, 1376, 1272, 1140, 1011, 954, 911, 820, 772, 760, 694, 655, 496 cm⁻¹; MS (ESI) m/z : 227 (100%), 115; HRMS (ESI) for C₁₃H₁₁N₂O₂ [M+H]⁺: calcd 227.0821, found 227.0824; Anal. Calcd for C₁₃H₁₀N₂O₂: C, 69.02; H, 4.46; N, 12.38. Found: C, 68.99; H, 4.40; N, 12.42.

2-Propyl-5-methylfuro[2,3-*d*]pyridazin-4(5*H*)-one (9b). Chromatography eluent: Heptane/Ether 6:4; Yield 3%; dark yellow oil; δ_{H} (CDCl₃): 8.10 (d, $J = 0.8$ Hz, 1H, H-7), 6.66 (q, $J = 1.0$ Hz, 1H, H-3), 3.85 (s, 3H, NCH₃), 2.76 (td, $J = 7.5, 0.9$ Hz, 2H, H-1'), 1.76 (h, $J = 7.5$ Hz, 2H, H-2'), 1.00 (t, $J = 7.5$ Hz, 3H, H-3'); δ_{C} (CDCl₃): 162.25 (C-2), 158.96 (C-4), 152.32 (C-7a), 125.82 (C-7), 123.96 (C-3a), 102.52 (C-3), 39.59 (NCH₃), 30.22 (C-1'), 20.94 (C-2'), 14.09 (C-3'); ν_{max} (liquid film): 2962, 2932, 2874, 1674, 1565, 1463, 1379, 1269, 1125, 1018, 831, 766, 528 cm⁻¹; MS (ESI) m/z : 193, 164 (100%), 139; HRMS (ESI) for C₁₀H₁₃N₂O₂ [M+H]⁺: calcd 193.0977, found 193.0975; Anal. Calcd for C₁₀H₁₂N₂O₂: C, 62.49; H, 6.29; N, 14.57. Found: C, 62.32; H, 6.23; N, 14.49.

2-*t*-Butyl-5-methylfuro[2,3-*d*]pyridazin-4(5*H*)-one (9c). Chromatography eluent: Hexane/EtOAc 1:1; Yield 52%; yellowish oil; δ_{H} (CDCl₃): 8.12 (d, $J = 0.8$ Hz, 1H, H-7), 6.65 (d, $J = 0.8$ Hz, 1H, H-3), 3.86 (s, 3H, NCH₃), 1.37 (s, 9H, *t*-Bu); δ_{C} (CDCl₃): 169.99 (C-2), 159.02 (C-4), 152.20 (C-7a), 125.90 (C-7), 123.70 (C-3a), 99.73 (C-3), 39.56 (NCH₃), 33.32 [C(CH₃)], 28.74 [C(CH₃)]; ν_{max} (KBr): 3119, 3051, 2970, 2873, 1682, 1558, 1378, 1278, 1143, 1063, 1019, 956, 927, 826, 766, 540 cm⁻¹; MS (ESI) m/z : 207 (100%), 192, 177, 139; HRMS (ESI) for C₁₁H₁₅N₂O₂ [M+H]⁺: calcd 207.1134, found 207.1129; Anal. Calcd for C₁₁H₁₄N₂O₂: C, 64.06; H, 6.84; N, 13.58. Found: C, 63.96; H, 6.80; N, 13.49.

General procedure for the preparation of 2-substituted 6-methylthio[2,3-*d*]pyridazin-7(6*H*)-ones (8a,b) and 2-substituted 5-methylthio[2,3-*d*]pyridazin-4(5*H*)-ones (10a,b):

To a solution of 5-alkynyl-4-chloro- (**1a,b**) or 4-alkynyl-5-chloro-2-methylpyridazin-3(2*H*)-ones (**4a,b**) (1 mmol) in DMF (4.6 mL) Na₂S·9H₂O (0.53 g, 2.2 mmol) was added. The reaction mixture was stirred at 60°C until total consumption of the starting material (TLC analysis and/or DCI-MS). The reaction mixture was then poured into water (65 mL) and extracted with CH₂Cl₂ (3x75 mL). After drying over MgSO₄, the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography when indicated.

2-Phenyl-6-methylthio[2,3-*d*]pyridazin-7(6*H*)-one (8a). No column chromatography was performed. Yield 72%; light brown solid; mp 191.5°C (Ethanol); δ_{H} (CDCl₃): 8.15 (s, 1H, H-4), 7.71-7.66 (m, 2H, H_{Ph}-2,6), 7.49-7.39 (m, 4H, H-3 and H_{Ph}-3,4,5), 3.88 (s, 3H, NCH₃); δ_{C} (CDCl₃): 157.27, 153.34 (C-7 or C-7a), 140.17 (C-3a), 135.98 (C-2), 132.74 (C_{Ph}-1), 132.72 (C-4), 129.67 (C_{Ph}-4), 129.32 (C_{Ph}-3,5), 126.80 (C_{Ph}-2,6), 118.26 (C-3), 39.32 (NCH₃); ν_{max} (KBr): 3088, 3058, 1636, 1468, 1349, 1242, 1021, 852, 753, 682, 455 cm⁻¹; MS (ESI) *m/z*: 243 (100%), 186, 115; HRMS (ESI) for C₁₃H₁₁N₂OS [M+H]⁺: calcd 243.0592, found 243.0585; Anal. Calcd for C₁₃H₁₀N₂OS: C, 64.44; H, 4.16; N, 11.56. Found: C, 64.47; H, 4.10; N, 11.66.

2-Propyl-6-methylthio[2,3-*d*]pyridazin-7(6*H*)-one (8b). Chromatography eluent: Heptane/EtOAc 6:4; Yield 60%; light yellow solid; mp 67.5°C (Hexane/Petroleum ether); δ_{H} (CDCl₃): 8.07 (s, 1H, H-4), 7.00 (t, *J* = 1.1 Hz, 1H, H-3), 3.86 (s, 3H, NCH₃), 2.91 (td, *J* = 7.5, 1.1 Hz, 2H, H-1'), 1.79 (h, *J* = 7.5 Hz, 2H, H-2'), 1.01 (t, *J* = 7.3 Hz, 3H, H-3'); δ_{C} (CDCl₃): 157.36, 155.96 (C-7 or C-7a), 139.72 (C-3a), 135.57 (C-2), 132.54 (C-4), 120.03 (C-3), 39.24 (NCH₃), 32.75 (C-1'), 24.52 (C-2'), 13.54 (C-3'); ν_{max} (KBr): 3093, 2959, 2870, 1629, 1567, 1464, 1345, 1224, 1024, 878, 669, 445 cm⁻¹; MS (ESI) *m/z*: 209, 180 (100%); HRMS (ESI) for C₁₀H₁₃N₂OS [M+H]⁺: calcd 209.0749, found 209.0742; Anal. Calcd for C₁₀H₁₂N₂OS: C, 57.67; H, 5.81; N, 13.45. Found: C, 57.60; H, 5.83; N, 13.39.

2-Phenyl-5-methylthio[2,3-*d*]pyridazin-4(5*H*)-one (10a). No column chromatography was performed. Yield 79%; brownish solid; mp 212°C (decomp, Ethanol); δ_{H} (CDCl₃): 8.17 (d, *J* = 0.8 Hz, 1H, H-7), 7.89 (d, *J* = 0.8 Hz, 1H, H-3), 7.70-7.66 (m, 2H, H_{Ph}-2,6), 7.47-7.37 (m, 3H, H_{Ph}-3,4,5), 3.87 (s, 3H, NCH₃); δ_{C} (CDCl₃): 157.66 (C-4), 149.86 (C-7a), 138.82 (C-3a), 137.14 (C-2), 132.69 (C_{Ph}-1), 131.37 (C-7), 129.48 (C_{Ph}-4), 129.31 (C_{Ph}-3,5), 126.65 (C_{Ph}-2,6), 119.88 (C-3), 39.40 (NCH₃); ν_{max} (KBr): 3075, 2925, 1651, 1467, 1240, 1049, 954, 881, 758, 689, 627, 525 cm⁻¹; MS (ESI) *m/z*: 243 (100%), 186, 115; HRMS (ESI) for C₁₃H₁₁N₂OS [M+H]⁺: calcd 243.0592, found 243.0593; Anal. Calcd for C₁₃H₁₀N₂OS: C, 64.44; H, 4.16; N, 11.56. Found: C, 64.39; H, 4.08; N, 11.50.

2-Propyl-5-methylthio[2,3-*d*]pyridazin-4(5*H*)-one (10b). Chromatography eluent: Heptane/Ether 1:1; Yield 19%; dark yellow oil; δ_{H} (CDCl₃): 8.11 (d, *J* = 0.6 Hz, 1H, H-7), 7.41 (q, *J* = 0.8 Hz, 1H, H-3), 3.85 (s, 3H, NCH₃), 2.90 (td, *J* = 7.5, 1.0 Hz, 2H, H-1'), 1.78 (h, *J* = 7.3 Hz, 2H, H-2'), 1.01 (t, *J* = 7.3 Hz, H-3'); δ_{C} (CDCl₃): 157.65 (C-4), 152.37 (C-7a), 138.62 (C-3a), 136.52 (C-2), 131.46 (C-7), 121.50 (C-3), 39.31 (NCH₃), 32.49 (C-1'), 24.48 (C-2'), 13.52 (C-3'); ν_{max} (liquid film): 3094, 3032, 2962, 2931, 2901, 2870, 1637, 1481, 1042, 954, 843, 766, 631, 497 cm⁻¹; MS (ESI) *m/z*: 209, 180 (100%), 167;

HRMS (ESI) for C₁₀H₁₃N₂OS [M+H]⁺: calcd 209.0749, found 209.0753; Anal. Calcd for C₁₀H₁₂N₂OS: C, 57.67; H, 5.81; N, 13.45. Found: C, 57.59; H, 5.70; N, 13.32.

Preparation of 5-*t*-Butylethynyl-4-chloro-2-methyl- (7c) and 4-*t*-Butylethynyl-5-chloro-2-methylpyridazin-3(2*H*)-one (9c):

The procedure for the preparation of these compounds is described in a previous publication.¹

5-*t*-Butylethynyl-4-chloro-2-methylpyridazin-3(2*H*)-one (7c). Chromatography eluent: Heptane/EtOAc 8:2; Yield 30%; brown oil; δ_{H} (CDCl₃): 7.62 (s, 1H, H-6), 3.80 (s, 3H, NCH₃), 1.35 (s, 9H, *t*-Bu); δ_{C} (CDCl₃): 157.16 (C-3), 136.59 (C-6), 130.21 (C-4), 126.72 (C-5), 114.00 (C-2'), 72.15 (C-1'), 40.88 (NCH₃), 30.43 [C(CH₃)₃], 28.74 [C(CH₃)₃]; ν_{max} (liquid film): 2972, 2871, 2360, 2229, 1657, 1587, 1367, 1286, 1241, 864, 676 cm⁻¹; MS (ESI) m/z: 225 (100%), 210, 132; HRMS (ESI) for C₁₁H₁₄N₂OCl [M+H]⁺: calcd 225.0795, found 225.0802; Anal. Calcd for C₁₁H₁₃N₂ClO: C, 58.80; H, 5.83; N, 12.47. Found: C, 58.84; H, 5.93; N, 12.37.

4-*t*-Butylethynyl-5-chloro-2-methylpyridazin-3(2*H*)-one (9c). Chromatography eluent: Heptane/EtOAc 8:2; Yield 30%; light yellow solid; mp 94.2°C (Hexane/Ether); δ_{H} (CDCl₃): 7.72 (s, 1H, H-6), 3.75 (s, 3H, NCH₃), 1.37 (s, 9H, *t*-Bu); δ_{C} (CDCl₃): 158.90 (C-3), 139.20 (C-5), 135.86 (C-6), 124.00 (C-4), 116.99 (C-2'), 71.48 (C-1'), 40.45 (NCH₃), 30.53 [C(CH₃)₃], 28.97 [C(CH₃)₃]; ν_{max} (KBr): 3085, 3055, 2972, 2930, 2214, 1644, 1564, 1456, 1288, 1246, 1036, 947, 852, 630 cm⁻¹; MS (ESI) m/z: 225, 189, 183, 157, 127 (100%); HRMS (ESI) for C₁₁H₁₄N₂OCl [M+H]⁺: calcd 225.0795, found 225.0785; Anal. Calcd for C₁₁H₁₃N₂ClO: C, 58.80; H, 5.83; N, 12.47. Found: C, 58.67; H, 5.80; N, 12.45.

ACKNOWLEDGMENTS

Support by RAFO RUCA is gratefully acknowledged. Dr. B. Maes thanks the Fund for Scientific Research (FWO-Vlaanderen) for an appointment as Post-doctoral Fellow. The authors wish to thank Prof. Dr. E. Esmans and Dr. F. Lemière for the use of their MS facilities, and Ing. J. Aerts, J. Schrooten, Ing. W. Van Dongen, V. Van Heurck and Ing. J. Verreydt for technical assistance.

REFERENCES

1. O. R'kyek, B. U. W. Maes, T. H. M. Jonckers, G. L. F. Lemière, and R. A. Dommissie, *Tetrahedron*, 2001, **57**, 10009.
2. For transformations of the triple bond to several other functional groups see: Richard Larock 'Comprehensive Organic Transformations: A Guide to Functional Group Transformations' foreword by H. C. Brown, VCH Publishers, Inc. New York, 1989.

3. B. U. W. Maes, J. Košmrlj, and G. L. F. Lemière, *J. Heterocycl. Chem.*, 2002, **39**, 535.
4. B. U. W. Maes, O. R'kyek, J. Košmrlj, G. L. F. Lemière, E. Esmans, J. Rozenski, R. A. Dommissie, and A. Haemers, *Tetrahedron*, 2001, **57**, 1323.
5. After work-up of the reaction mixtures (see EXPERIMENTAL Part: General procedures) ¹H-NMR and DCI-MS spectra revealed the presence of several reaction products which could not be separated:
4a + NaSCH₃/dioxane: 5-chloro-2-methyl-4-[(*E* and *Z*)-2-methylsulfanyl-2-phenylvinyl]pyridazin-3(2*H*)-one.
4b + NaOCH₃/dioxane: 5-chloro-4-[(1*E* and 1*Z*)-2-methoxypent-1-enyl]-2-methylpyridazin-3(2*H*)-one and unidentified compound.
4b + NaSCH₃/dioxane: 5-chloro-2-methyl-4-[(1*E* and 1*Z*)-2-methylsulfanylpent-1-enyl]pyridazin-3(2*H*)-one.
6. J. W. Lyga, *J. Heterocycl. Chem.*, 1988, **25**, 1757.
7. (a) V. Dal Piaz, M. P. Giovannoni, C. Castellana, J. M. Palacios, J. Beleta, T. Doménech, and V. Segarra, *Eur. J. Med. Chem.*, 1998, **33**, 789; (b) V. Dal Piaz, M. P. Giovannoni, and C. Castellana, *J. Med. Chem.*, 1997, **40**, 1417; (c) M. Yamaguchi, N. Maruyama, T. Koga, K. Kamei, M. Akima, T. Kuroki, M. Hamana, and N. Ohi, *Chem. Pharm. Bull.*, 1995, **43**, 236; (d) S. K. Robev, E. Kloutchek-Popova, and M. A. Dicheva, *Dokl. Bolg. Akad. Nauk.*, 1983, **36**, 1555; (e) I. Maeba, V. Laohathai, and S. Yoshina, *Yakugaku Zasshi*, 1974, **94**, 922.
8. (a) M. Tišler and B. Stanovnik, in 'Condensed Pyridazines including Cinnolines and Phthalazines', ed. by R. N. Castle, An Interscience® Publication, J. Wiley and Sons, Inc., 1973, pp. 902-906 and 933-938 and references cited therein; (b) R. G. Jones, *J. Am. Chem. Soc.*, 1956, **78**, 159; (c) E. Bisagni, J. P. Marquet, J. André-Louisfert, A. Cheutin, and F. Feinte, *Bull. Soc. Chim. Fr.*, 1967, 2796; (d) M. Robba, B. Roques, and M. Bonhomme, *Bull. Soc. Chim. Fr.*, 1967, 2495; (e) M. Robba and M. C. Zaluski, *Bull. Soc. Chim. Fr.*, 1968, 4959.
9. (a) J. J. Li and G. W. Gribble, 'Palladium in Heterocyclic Chemistry: A Guide for the Synthetic Chemist', Tetrahedron Organic Chemistry Series Vol. 20, ed. by J. E. Baldwin, FRS & R. M. Williams, Pergamon Press, 2000, pp. 369 and 393 and references cited therein; (b) D. E. Ames, J. C. Mitchell, and C. Takundwe, *J. Chem. Res. (M)*, 1985, 1682; (c) D. E. Ames, J. C. Mitchell, and C. C. Takundawa, *J. Chem. Res. (S)*, 1985, 144.
10. N. G. Kundu, M. Pal, J. S. Mahanty, and M. De, *J. Chem. Soc., Perkin Trans. 1*, 1997, 2815 and references cited therein.